Quest Diagnostics Incorporated (DGX)
NYSE · Healthcare · Medical - Diagnostics & Research
Profile
Quest Diagnostics Incorporated
- Exchange
- NYSE
- Ticker
- DGX
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- US
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Key facts
Quest Diagnostics Incorporated: key facts
- Quest Diagnostics Incorporated (NYSE: DGX) is a Medical - Diagnostics & Research company in the Healthcare sector.
- In fiscal 2025, Quest Diagnostics Incorporated reported revenue of $11.0B and net income of $992.0M.
- Revenue grew 0.6% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $11.8B and net income was $1.1B.
MonkScore
Quest Diagnostics Incorporated's MonkScore
MonkScore
MonkScore range: 70–80
as of October 2026
Sector rank: 193 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth60–70
- Profitability60–70
- Quality50–60
- Market Conviction60–70
- Safety40–50
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Quest Diagnostics Incorporated's annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $11.8B | $11.0B | $9.9B | $9.3B | $9.9B | $10.8B |
| Gross profit | $3.9B | $3.5B | $3.2B | $3.1B | $3.4B | $4.2B |
| Operating income | $1.7B | $1.6B | $1.3B | $1.3B | $1.4B | $2.4B |
| Net income | $1.1B | $992.0M | $871.0M | $854.0M | $946.0M | $2.0B |
| Operating cash flow | $2.0B | $1.9B | $1.3B | $1.3B | $1.7B | $2.2B |
| Capital expenditure | -$576.0M | -$527.0M | -$425.0M | -$408.0M | -$404.0M | -$403.0M |
| Free cash flow | $1.4B | $1.4B | $909.0M | $864.0M | $1.3B | $1.8B |
| Total debt | $6.3B | $6.9B | $7.1B | $5.5B | $4.7B | $4.8B |
| Cash | $797.0M | $420.0M | $549.0M | $686.0M | $315.0M | $872.0M |
Revenue growth a year
- 1-year
- 11.8%
- 3-year
- 3.7%
- 4-year
- 0.6%
Compound growth between fiscal years.
Peers
Similar companies
- Sotera Health CompanyNASDAQ:SHCMonkScore range: 70–80
- IQVIA Holdings Inc.NYSE:IQVMonkScore range: 70–80
- Agilent Technologies, Inc.NYSE:AMonkScore range: 70–80
- Mettler-Toledo International Inc.NYSE:MTDMonkScore range: 90–100
- Illumina, Inc.NASDAQ:ILMNMonkScore range: 90–100
- CareDx, IncNASDAQ:CDNAMonkScore range: 90–100
- Medpace Holdings, Inc.NASDAQ:MEDPMonkScore range: 90–100
- IDEXX Laboratories, Inc.NASDAQ:IDXXMonkScore range: 90–100
Compare
Compare with
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.